Abstract graphic of an eye
Investor Relations

Press Release

Genomic Solutions -a Harvard Bioscience company- and Bruker Daltonics Sign Value Added Reseller Agreement

January 7, 2003
Genomic Solutions -a Harvard Bioscience company- and Bruker Daltonics Sign Value Added Reseller Agreement

HOLLISTON, Mass., Jan 7, 2003 (BUSINESS WIRE) -- Genomic Solutions, a subsidiary of Harvard Bioscience, Inc. (NASDAQ: HBIO), and Bruker Daltonics, Inc. (NASDAQ: BDAL) are pleased to announce the signing of a non-exclusive worldwide reseller agreement. Under this agreement, Bruker Daltonics will incorporate Genomic Solutions' ProFound™ and Sonar MS/MS™ search engines, part of the Investigator™ brand of proteomic research tools, as integral components of their line of mass spectrometry products. These search engines will work with Bruker's data analysis software ProteinScape and BioTools™ to streamline and improve the accuracy of protein identification via MALDI or MS/MS.

Jeff Williams, President of Genomic Solutions, commented: "The combination of Bruker Daltonics' innovative mass spectrometry instrumentation with our powerful searching algorithms and quality-controlled scoring routines will add great confidence and value to protein identification and characterization. We are pleased that such a leading mass spectrometry firm has chosen our ProFound and Sonar MS/MS search engines."

Herbert Thiele, Bruker Daltonics' Director of Bioinformatics, added: "It is Bruker Daltonics' strategy within bioinformatics software to give customers specific options. If one is identifying proteins the use of different search engines provides more confidence in the results."

About Harvard Bioscience, Inc.

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily scientific instruments, used to accelerate drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries through its direct sales force, its 1,000 page catalog (and various other specialty catalogs), and through its distributors, including Amersham Biosciences and PerkinElmer. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Austria and Belgium with sales facilities in Japan, France and Canada. For more information please visit www.harvardbioscience.com

About Bruker Daltonics

Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics is also a worldwide leader in supplying systems for substance detection and pathogen detection in security, defense and anti-terrorism. For more information about Bruker Daltonics, please visit www.bdal.com.

The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements or inferences about the significance of reseller agreements on the Company's financial condition, results of operations or stock price. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.

Investor information:
Harvard Bioscience, Inc.
David Green, 508/893-8999

© 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.